BioCentury
ARTICLE | Company News

Valeant Pharmaceuticals, Pharming deal

August 22, 2016 7:00 AM UTC

Pharming will pay Valeant $60 million up front and up to $65 million in sales milestones to reacquire North American commercialization rights to Ruconest conestat alfa. The recombinant human C1 ester...